Review

Anti-virulence therapeutics: A paradigm shift beyond conventional antibiotics

Mohammed Naveez Valathoor 1,*

1 School of Biosciences and Technology, Vellore Institute of Technology, X595+H4M, VIT University, Vellore, Tamil Nadu 632014 India.

* Correspondence: naveezbiotech@gmail.com (M.N.V.)

Citation: Valathoor, M.N. Anti-virulence therapeutics: A paradigm shift beyond conventional antibiotics. Glob. Jour. Bas. Sci. 2025, 1(12). 1-6.

Received: June 29, 2025

Revised: october 25, 2025

Accepted: October 27, 2025

Published: October 29, 2025

doi: 10.63454/jbs20000065

ISSN: 3049-3315

Volume 1; Issue 12

Download PDF file

Abstract: The rapid global escalation of antimicrobial resistance (AMR) has emerged as one of the most pressing public health challenges of the twenty-first century. Conventional antibiotics, which exert their effects by killing or inhibiting the growth of microorganisms, impose strong selective pressure that accelerates the emergence and dissemination of resistant strains. This growing inefficacy has prompted the exploration of alternative therapeutic strategies. Anti-virulence therapeutics represent a promising paradigm shift that aims to neutralize microbial pathogenicity without directly affecting microbial viability. By targeting virulence determinants such as toxins, adhesion factors, secretion systems, quorum sensing networks, and immune evasion mechanisms, these approaches seek to disarm pathogens and enhance host-mediated clearance while minimizing selective pressure for resistance. This review provides a comprehensive overview of microbial virulence mechanisms, the molecular targets exploited by anti-virulence strategies, recent advances in drug development, and emerging clinical applications. We also discuss the advantages, limitations, and future prospects of anti-virulence therapies as part of next-generation infectious disease management.

Keywords: Anti-virulence therapy; antimicrobial resistance; quorum sensing; bacterial toxins; pathogenicity; host–pathogen interaction

1. Introduction

The introduction of antibiotics stands as one of the most transformative achievements in modern medicine. It fundamentally altered the prognosis of bacterial infections, converting previously fatal diseases into manageable conditions. This therapeutic revolution became the cornerstone for advancements across healthcare, enabling the safe performance of complex medical interventions—including major surgery, chemotherapy, organ transplantation, and neonatal care—that would otherwise be prohibitively risky due to infectious complications [1,2]. However, this cornerstone is eroding. Decades of excessive, and often inappropriate, antibiotic use in human medicine, agriculture, and aquaculture have exerted relentless selective pressure on microbial populations. This has catalyzed the rapid emergence and global spread of antimicrobial resistance (AMR), a phenomenon now recognized as one of the greatest threats to global public health [1,2]. The efficacy of our most critical drugs is diminishing, threatening to reverse a century of medical progress. Pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant Enterobacteriaceae (CRE), and multidrug-resistant Pseudomonas aeruginosa have become formidable adversaries in healthcare settings, contributing to soaring rates of treatment failure, prolonged hospital stays, increased mortality, and significant economic burden [3].

The mechanistic basis of traditional antibiotics—targeting essential bacterial processes like cell wall synthesis, protein production, DNA replication, and core metabolic pathways—is also the root of their vulnerability. While these bactericidal or bacteriostatic actions are potent, they create an intense Darwinian selection for resistant mutants. Surviving bacteria, often through genetic mutations or the acquisition of resistance genes via horizontal gene transfer, proliferate and disseminate [4]. Compounding this crisis is the stark inadequacy of the new antibiotic pipeline, which has failed to keep pace with the evolution of resistance. This convergent crisis—accelerating resistance and a stagnant therapeutic pipeline—has spurred an urgent reevaluation of our antimicrobial strategy. The paradigm is shifting from a purely lethal approach to more nuanced, targeted interventions. Among the most promising alternatives is anti-virulence therapy [5]. This innovative strategy diverges from the traditional goal of killing bacteria or halting their growth. Instead, it aims to disarm the pathogen by specifically disrupting the molecular tools—virulence factors—it uses to establish infection and cause disease.

The conceptual foundation of anti-virulence therapy rests on the principle that pathogenicity is not an intrinsic property of a microbe, but is instead mediated by a repertoire of specialized factors. These virulence factors—such as toxins, adhesins, invasins, secretion systems, and biofilm-forming apparatuses—enable microbes to colonize host tissues, evade immune defenses, acquire nutrients, and inflict damage [6]. By administering agents that selectively inhibit the production or function of these factors, the pathogen can be rendered essentially harmless, or “avirulent.” Subsequently, the host’s innate immune system can clear the benign infection. Crucially, because this approach does not directly threaten bacterial survival or reproduction, it is theorized to exert significantly weaker selective pressure for the development of resistance compared to traditional antibiotics [6].

This review will explore the scientific and translational landscape of anti-virulence therapy. It will examine the molecular basis of key virulence mechanisms, survey the most promising anti-virulence targets currently under investigation, highlight progress in therapeutic development (including small molecules, biologics, and peptide-based agents), and critically discuss the potential advantages, challenges, and future directions for implementing this resistance-robust strategy in clinical practice.

2. Molecular basis of microbial virulence

The capacity of a microorganism to cause disease, known as virulence, is not a simple attribute but a complex phenotype arising from the precisely orchestrated expression of numerous genetic elements. This multifactorial trait is governed by a diverse arsenal of specialized molecules and systems, collectively termed virulence factors, which enable pathogens to colonize host niches, evade or subvert immune defenses, acquire nutrients, and ultimately inflict damage. These coordinated processes facilitate the multi-stage progression of infection, from initial adherence to tissue invasion and systemic dissemination. Key virulence determinants can be categorized into several interconnected functional classes, including structural adhesins, potent toxins, sophisticated secretion systems, communal biofilm formation mechanisms, and active immune evasion strategies [7]. Understanding this molecular repertoire is essential for developing targeted therapeutic interventions.

The foundational step in most infections is the stable attachment of the pathogen to host tissues, a process mediated by adhesins. These surface-exposed structures, which include pili, fimbriae, and afimbrial adhesin proteins, act as specific molecular tethers. They recognize and bind with high affinity to complementary receptors on host cells, such as glycoproteins or glycolipids. This specific adhesion is critical for establishing a foothold against mechanical clearance mechanisms like fluid flow and is often a prerequisite for the subsequent deployment of other virulence factors [8]. Following successful attachment, pathogens frequently deploy an array of toxins and enzymes designed to disrupt host physiology. These agents can cause direct cytolytic damage, interfere with intracellular signaling, and break down tissue barriers to promote invasion. Notable examples include pore-forming toxins that lyse host cells by creating channels in their membranes, proteases that degrade structural proteins, and exotoxins with enzymatic activity. The latter category includes toxins like cholera toxin, which disrupts ion transport leading to profound diarrhea, and diphtheria toxin, which halts host protein synthesis, demonstrating how targeted molecular sabotage can drive disease pathology [9].  

Beyond the secretion of toxins into the extracellular environment, many Gram-negative pathogens employ highly specialized nanomachine-like structures known as secretion systems to directly manipulate host cell functions. Type III, Type IV, and Type VI Secretion Systems function as molecular syringes, injecting bacterial effector proteins directly into the cytosol of eukaryotic host cells. Once inside, these effector proteins act as sophisticated saboteurs, modulating a wide range of cellular processes. They can manipulate cytoskeletal dynamics to force their own uptake, inhibit phagocytosis, disrupt programmed cell death pathways, and suppress pro-inflammatory signaling. This direct injection system allows the pathogen to create a protected intracellular niche conducive to replication and to dampen the host’s immune response from within [10]. Furthermore, bacterial populations often act in a coordinated manner rather than as individual cells, a behavior regulated by quorum sensing (QS) networks. QS involves the production, release, and population-wide detection of small diffusible signaling molecules called autoinducers. As cell density increases and autoinducer concentration crosses a threshold, it triggers a synchronized shift in gene expression across the bacterial community. This enables the population to collectively activate virulence programs—such as toxin production and biofilm formation—only when their numbers are sufficient to overcome host defenses, thereby mounting a synchronized attack on the host [11].

A paramount strategy for long-term persistence and enhanced virulence is the formation of biofilms. These are structured, multicellular communities of microbes encased within a self-produced extracellular polymeric substance (EPS) matrix. Biofilm formation represents a fundamental shift from a free-floating, planktonic lifestyle to a surface-attached, communal mode of growth that confers remarkable resilience. The EPS matrix acts as a formidable physical and chemical barrier, significantly limiting the penetration of both antimicrobial agents and host immune effectors like complement and phagocytes. Within biofilms, gradients of nutrients and oxygen create zones of slowed metabolism, rendering bacterial cells highly tolerant to conventional antibiotics that typically target actively dividing cells. This environment also facilitates horizontal gene transfer, accelerating the spread of antibiotic resistance and virulence genes among community members. Consequently, biofilms are central to chronic, difficult-to-eradicate infections associated with medical implants and in conditions such as cystic fibrosis, making them a critical focal point in the study of microbial pathogenicity [12].

Figure 1. Anti-virulence therapeutics: A new approach. It shows the major approaches for disarming pathogens without killing to reduce resistance development.

3. Rationale for anti-virulence therapeutics

Anti-virulence therapy (Figure 1) represents a fundamental conceptual departure from traditional bactericidal and bacteriostatic approaches. Instead of directly killing bacteria or inhibiting their essential growth processes, this strategy aims to disarm pathogens by specifically targeting the molecular tools they use to cause disease—their virulence factors. These factors, such as toxins, adhesion molecules, and communication systems, are often non-essential for bacterial survival under laboratory conditions but are crucial for successful infection within a host. The central hypothesis is that by selectively inhibiting these pathogenicity mechanisms, the microbe can be rendered harmless and subsequently cleared by the host’s innate immune defenses. This indirect approach is theorized to exert significantly reduced selective pressure for the emergence of resistance, as the therapeutic target does not directly threaten bacterial viability or reproduction [13]. Furthermore, in a natural environment, a pathogen that has lost its virulence may be at a competitive disadvantage and be outcompeted by its virulent counterparts, a phenomenon that could further limit the fixation and spread of any resistant mutants that might arise [14].

An additional and critical advantage of anti-virulence strategies lies in their potential for precision and ecological conservation. Traditional broad-spectrum antibiotics act indiscriminately, devastating not only the pathogen but also the complex and beneficial communities of commensal microbiota. This dysbiosis can lead to a host of complications, including opportunistic infections like Clostridium difficile colitis, impaired nutrient metabolism, and weakened colonization resistance against future pathogens. By targeting virulence factors that are often specific to a particular pathogen or group, anti-virulence agents may spare the commensal flora, thereby preserving the microbial ecosystem’s health and protective functions and reducing the collateral damage associated with conventional antibiotic therapy [15].

Finally, anti-virulence therapeutics are not envisioned solely as standalone replacements for antibiotics but also as powerful partners in combination therapy. When used synergistically with conventional antibiotics, they can enhance overall treatment efficacy and potentially shorten treatment duration. The rationale is that an anti-virulence agent can “cripple” the pathogen—for instance, by inhibiting its protective biofilm, neutralizing its toxins, or disrupting its ability to invade tissues—thereby making it more susceptible to the killing action of a co-administered antibiotic and to host immune clearance. This multi-pronged strategy can lower the effective dose of the traditional antibiotic required, potentially mitigating its side effects and further delaying the development of resistance [16].

4. Major anti-virulence targets

The development of anti-virulence therapeutics focuses on disrupting specific, non-essential pathways critical to pathogenesis. By targeting the sophisticated systems bacteria use to establish and maintain infection, these strategies aim to render pathogens harmless while minimizing selective pressure for resistance. The most promising and actively researched targets include the mechanisms of bacterial communication, toxin production, host cell attachment, community formation, and host cell subversion.

4.1 Quorum sensing inhibition

Quorum sensing (QS) is a cell-density-dependent communication system that allows bacterial populations to coordinate collective behaviors like virulence factor production and biofilm formation. Inhibiting this communication—a strategy termed “quorum quenching”—effectively disarms the pathogen by preventing it from launching a synchronized attack. Potential inhibitors function by degrading the signaling molecules (autoinducers), by competitively blocking their receptors, or by interfering with downstream regulatory proteins. This approach has shown significant efficacy in attenuating virulence in model systems, particularly against pathogens like Pseudomonas aeruginosa and various Vibrio species, where QS inhibition can reduce toxin secretion, impair biofilm maturation, and enhance bacterial susceptibility to both antibiotics and host immune responses [17, 18].

4.2 Toxin neutralization

Many pathogens cause the most acute symptoms of disease through the action of potent exotoxins. Anti-virulence strategies therefore include direct toxin neutralization, which prevents host tissue damage without exerting any direct effect on bacterial viability. This can be achieved through several modalities: small molecules that inhibit toxin enzymatic activity or receptor binding, monoclonal antibodies that bind and sequester toxins, and toxoid vaccines that pre-emptively induce protective immunity. The most prominent clinical success in this area is the use of monoclonal antibodies against Clostridioides difficile toxins A and B (Bezlotoxumab), which has been approved to reduce recurrence of C. difficile infection by neutralizing the primary mediators of colonic damage and inflammation [19].

4.3 Adhesion and invasion blockade

The initial step of infection—adhesion to host tissues—is a critical and vulnerable point in the pathogenic cascade. Blocking this interaction prevents colonization and subsequent disease establishment. Anti-adhesion strategies employ compounds known as “pilicides” or “adhesin blockers” that either inhibit the assembly or function of microbial adhesins (like pili and fimbriae) or act as receptor mimics that competitively bind to these adhesins, shielding host cells. Similarly, inhibitors can target bacterial invasins or host cell pathways required for internalization. This approach has demonstrated considerable promise in preclinical and some clinical settings for pathogens causing urinary tract infections (e.g., uropathogenic E. coli) and gastrointestinal diseases, offering the potential for highly specific and preventive interventions [20].

4.4 Biofilm disruption

Biofilms are a major driver of chronic, recalcitrant infections due to their inherent tolerance to antibiotics and host defenses. Anti-virulence agents aimed at biofilm disruption seek to dismantle this protective fortress. Potential targets include enzymes involved in synthesizing the extracellular polymeric substance (EPS) matrix, signaling molecules that regulate the biofilm lifecycle (like cyclic-di-GMP), and pathways for biofilm dispersal. By interfering with matrix integrity or bacterial signaling, these agents can prevent biofilm formation, break apart existing biofilms, or revert bacteria to a free-living, antibiotic-susceptible state. This not only restores the efficacy of co-administered conventional antibiotics but also re-exposes the bacteria to clearance by phagocytic immune cells [21].

4.5 Secretion system inhibitors

Specialized secretion systems (e.g., Type III, IV, VI) are complex molecular nanomachines used by many Gram-negative pathogens to inject effector proteins directly into host cells, subverting cellular functions and immune responses. Inhibiting these systems offers a powerful way to disarm intracellular pathogens. Strategies include developing small molecules that inhibit the assembly or the ATPase activity of the secretion apparatus, blocking the chaperones that guide effector proteins to the system, or creating specific inhibitors of the translocon pore that forms in the host cell membrane. By crippling this key virulence delivery mechanism, secretion system inhibitors can prevent bacterial manipulation of the host, reduce intracellular survival, and render the pathogen vulnerable to immune clearance, without affecting its growth in vitro [22].

5. Anti-virulence strategies against fungal and parasitic pathogens

The paradigm of anti-virulence therapy, while most advanced in the context of bacterial infections, conceptually extends to other major classes of pathogens. In fungal pathogens, key virulence traits are being actively explored as therapeutic targets. These include dimorphic morphogenesis (the ability to switch between yeast and invasive hyphal forms, as seen in Candida albicans), the formation of drug-resistant biofilms on medical devices and tissues, and sophisticated stress-response pathways that enable survival within the hostile host environment. Targeting the signaling cascades or molecular machinery that govern these processes, rather than essential fungal growth, offers a promising route to attenuate disease without driving the same level of resistance seen with conventional fungicides [23]. Similarly, parasitic pathogens possess a distinct repertoire of virulence mechanisms, many of which are absent in the host and thus represent attractive targets. These include specialized organelles for host cell invasion (e.g., the apical complex in apicomplexans like Plasmodium and Toxoplasma), complex lifecycle stage transitions, and sophisticated strategies for antigenic variation and immune system evasion. Disrupting these parasite-specific mechanisms could lead to novel classes of anti-malarial, anti-helminthic, or anti-protozoal agents that block disease progression and transmission [24].

6. Clinical progress and translational applications

The translation of anti-virulence strategies from concept to clinic is underway, with several agents demonstrating proof-of-concept in human trials. The most notable success is bezlotoxumab, a human monoclonal antibody that binds and neutralizes Clostridioides difficile toxin B. Its approval for use alongside antibiotics to prevent recurrent C. difficile infection validates the anti-virulence approach, as it significantly reduces recurrence rates by protecting the colonic epithelium without directly killing the bacterium or disrupting the commensal gut microbiota [25]. In other therapeutic areas, molecules designed to inhibit quorum sensing or disrupt biofilms are entering clinical evaluation, particularly for managing chronic infections. For example, anti-virulence agents are being investigated as adjunctive therapies in cystic fibrosis-associated pneumonia to improve lung function and break the cycle of chronic Pseudomonas aeruginosa infection by reducing biofilm burden and pyocyanin production [26]. A major area of focus is combination therapy, where anti-virulence agents are paired with conventional antimicrobials. The rationale is synergistic: the anti-virulence agent weakens the pathogen’s defenses (e.g., by disabling toxin production or dispersing a biofilm), thereby rendering it more susceptible to the killing action of the antibiotic. This strategy can enhance overall efficacy, lower the required antibiotic dose, shorten treatment duration, and, critically, delay the emergence of resistance by reducing the selective pressure exerted by the antibiotic alone [27].

7. Challenges, limitations, and future perspectives

Despite considerable promise, the development and deployment of anti-virulence therapeutics face significant scientific and practical hurdles. A primary scientific challenge is the redundancy and plasticity of virulence pathways. Pathogens may possess alternative mechanisms to achieve the same pathogenic outcome, allowing them to compensate for the inhibition of a single target. Furthermore, mutations that restore virulence function, though potentially less fitness-enhancing than antibiotic resistance mutations, could still arise and limit long-term efficacy [28]. From a translational standpoint, identifying which virulence factors are truly essential for causing disease in humans—as opposed to in animal models—and defining the appropriate patient populations (e.g., early colonizers vs. established chronic infections) remains complex [29]. Regulatory pathways also present a challenge. Current frameworks for antimicrobial approval are heavily geared toward demonstrating direct microbiological kill or growth inhibition. Defining clinically meaningful endpoints and establishing regulatory guidelines for agents that alleviate disease without reducing pathogen burden will require close collaboration between developers and regulatory agencies [30].

The future of anti-virulence therapy is being shaped by interdisciplinary technological advances. Systems biology, high-throughput genomics, and sophisticated host-pathogen interaction modeling are enabling the unbiased discovery of novel, clinically relevant virulence targets and the prediction of resistance mechanisms [31]. Furthermore, the convergence with precision medicine offers exciting potential: diagnostics that rapidly identify a pathogen’s virulence profile could guide the targeted use of specific anti-virulence agents. Similarly, host-directed therapies that bolster the immune system’s ability to clear disabled pathogens may be powerful synergistic partners [32]. As the crisis of antimicrobial resistance escalates globally, a fundamental shift in therapeutic strategy is necessary. Integrating anti-virulence therapeutics into the antimicrobial arsenal—and embedding them within global antimicrobial stewardship programs—represents a forward-looking, sustainable approach. By preserving our life-saving antibiotics and leveraging the host’s own defenses, this paradigm aims to outsmart pathogens rather than outpace them in a futile arms race of lethality, offering a more durable solution to infectious disease [33].

8. Conclusion

The escalating crisis of antimicrobial resistance necessitates a fundamental reimagining of our therapeutic strategies. Anti-virulence therapeutics represent a transformative and paradigm-shifting approach, moving the focus of infectious disease treatment from direct microbial lethality to precise pathogen disarming. This strategy capitalizes on a detailed understanding of microbial pathogenesis, deliberately targeting the sophisticated molecular machinery—such as toxins, adhesion systems, communication networks, and biofilm matrices—that bacteria, fungi, and parasites use to cause disease, rather than their core survival functions. This conceptual departure offers a multi-faceted promise: by exerting a weaker selective pressure, anti-virulence agents have the potential to dramatically reduce the rate of resistance development; by acting with precision, they can preserve the critical balance of the host’s commensal microbiota, avoiding the dysbiosis that drives secondary infections; and by crippling pathogen defenses, they can act synergistically with conventional antibiotics, enhancing efficacy and prolonging the clinical lifespan of our existing antimicrobial arsenal.

However, the full realization of this promise hinges on sustained and collaborative effort. Translating these innovative concepts into widely available treatments requires continued interdisciplinary research that bridges microbiology, structural biology, pharmacology, and immunology. It demands substantial clinical investment to navigate novel regulatory pathways and to define optimal therapeutic contexts, whether as standalone preventative measures, adjunctive therapies for chronic infections, or components of novel combination regimens. As the threat of untreatable infections grows, the development and integration of anti-virulence strategies are not merely an alternative but an essential component of a sustainable future for global public health. By aiming to neutralize disease rather than annihilate the pathogen, this paradigm offers a more sophisticated and potentially more durable defense in the enduring battle against infectious disease.

Author Contributions: Conceptualisation, M.N.V.; software, S.F.; investigation, M.N.V.;  writing—original draft preparation, M.N.V.; writing—review and editing, M.N.V.; visualisation, M.N.V.; supervision, M.N.V.; project administration, P.K.S. The author has read and agreed to the published version of the manuscript.

Funding: Not applicable.

Acknowledgments: We are grateful to the School of Biosciences and Technology, Vellore Institute of Technology, X595+H4M, VIT University, Vellore, Tamil Nadu 632014 India. for providing us all the facilities to carry out the entire work.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All the related data are supplied in this work or have been referenced properly.

References

  1. World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO; 2015.
  2. O’Neill J. Tackling drug-resistant infections globally: Final report and recommendations. London: Review on Antimicrobial Resistance; 2016.
  3. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: CDC; 2019.
  4. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–33.
  5. Allen RC, Popat R, Diggle SP, Brown SP. Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol. 2014;12(4):300–8.
  6. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol. 2007;3(9):541–8.
  7. Casadevall A, Pirofski LA. Virulence factors and their mechanisms of action: the view from infectious diseases. Infect Immun. 2009;77(9):351–62.
  8. Kline KA, Fälker S, Dahlberg S, Normark S, Henriques-Normark B. Bacterial adhesion mechanisms: host-microbe interactions in the post-genomic era. Nat Rev Microbiol. 2015;13(5):269–84.
  9. Schmitt CK, Meysick KC, O’Brien AD. Bacterial toxins: friends or foes? Nat Rev Microbiol. 2005;3(3):247–58.
  10. Cornelis GR. The type III secretion system: a versatile bacterial weapon for interaction with host cells. Nat Rev Microbiol. 2006;4(11):811–25.
  11. Rutherford ST, Bassler BL. Bacterial quorum sensing: its role in virulence and possibilities for its control. Cold Spring Harb Perspect Med. 2012;2(11):a012427.
  12. Flemming HC, Wingender J, Szewzyk U, Steinberg P, Rice SA, Kjelleberg S. Biofilms: an emergent form of bacterial life. Nat Rev Microbiol. 2016;14(9):563–75.
  13. Maura D, Ballok AE, Rahme LG. Considerations and caveats in anti-virulence drug development. Curr Opin Microbiol. 2016;33:41–6.
  14. Vale PF, McNally L, Doeschl-Wilson A, King KC, Popat R, Domingo-Sananes MR, et al. Beyond killing: can we find new ways to manage infection? Evol Appl. 2016;9(8):1055–67.
  15. Buffie CG, Pamer EG. Microbiota-mediated resistance against infectious diseases. Nat Rev Immunol. 2013;13(11):790–801.
  16. Dickey SW, Cheung GYC, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. PLoS Pathog. 2017;13(9):e1006516.
  17. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 2003;22(15):3803–15.
  18. Brackman G, Coenye T. Quorum sensing inhibitors as anti-biofilm agents. Pathog Dis. 2015;73(1):ftu016.
  19. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for prevention of recurrent Clostridioides difficile infection. N Engl J Med. 2017;376(4):305–17.
  20. Spaulding CN, Hultgren SJ. Adhesive organelles: Bacterial adhesion and invasion in host–microbe interactions. Microbiol Spectr. 2016;4(5).
  21. Koo H, Allan RN, Howlin RP, Stoodley P, Hall-Stoodley L. Targeting microbial biofilms: current and prospective therapeutic strategies. Nat Rev Microbiol. 2017;15(12):740–55.
  22. Marshall NC, Finlay BB. Targeting the type III secretion system to treat bacterial infections. Nat Rev Microbiol. 2018;16(7):635–46.
  23. Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4(2):119–28.
  24. Cowman AF, Berry D, Baum J. The host–parasite interaction in malaria: a systems perspective. Cell. 2016;167(3):610–24.
  25. Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):1025–44.
  26. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000;407(6805):762–4.
  27. Maura D, Rahme LG. Pharmacological inhibition of the Pseudomonas aeruginosa MvfR quorum-sensing system interferes with biofilm formation and potentiates antibiotic efficacy. Curr Opin Microbiol. 2017;39:156–63.
  28. Defoirdt T. Quorum-sensing systems as targets for antivirulence therapy. Trends Microbiol. 2018;26(4):313–28.
  29. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Microbiol. 2010;8(2):117–28.
  30. Rex JH, Eisenstein BI, Alder J, Goldberger M, Meyer R, Dane A, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Clin Infect Dis. 2013;56(9):1030–6.
  31. Kitano H. Systems biology of host–pathogen interactions. Nat Rev Microbiol. 2013;11(6):425–36.
  32. Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2018;17(1):35–56.
  33. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013;13(12):126–37.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Global Journal of Basic Science and/or the editor(s). Global Journal of Basic Science and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. 

Copyright: © 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Loading

Bibliography